Melphalan Hikma (Melphalan)

Melphalan works by forming covalent bonds with DNA, creating intra‑ and interstrand cross‑links. These cross‑links block DNA replication and transcription, leading to cell cycle arrest and programmed cell death, particularly in rapidly dividing cancer cells that have limited ability to repair DNA damage.

The dose of melphalan is individualized and set by the prescribing oncologist or hematologist. Dosage depends on factors such as the specific cancer being treated, patient weight, renal function, prior therapies, and overall health status. Only a qualified healthcare professional can determine the appropriate regimen.

Melphalan is classified as potentially teratogenic and is contraindicated during pregnancy. It can also be excreted in breast milk and may harm a nursing infant. Women who are pregnant, planning to become pregnant, or breastfeeding should avoid melphalan and discuss alternative options with their physician.

To order Melphalan Hikma, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Melphalan belongs to the nitrogen‑mustard class of alkylating agents, sharing a DNA‑cross‑linking mechanism with drugs such as cyclophosphamide and chlorambucil. Compared with some newer targeted therapies, melphalan has a broader cytotoxic profile but may cause more pronounced myelosuppression. Choice of therapy depends on cancer type, prior treatment history and individual patient tolerance.

Melphalan Hikma should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. The product should be kept in its original packaging until use, and handling should follow aseptic techniques to maintain sterility for intravenous administration.

Melphalan Hikma is administered as an intravenous infusion by a qualified healthcare professional. The infusion rate and duration are determined by the prescribing physician based on the treatment protocol. Administration is typically performed in a clinical setting where vital signs and blood counts can be monitored closely.

Serious risks associated with melphalan include secondary malignancies such as acute leukemia, severe infections due to profound neutropenia, and pulmonary toxicity like interstitial pneumonitis or fibrosis. Patients should be monitored regularly for signs of infection, respiratory symptoms, and changes in blood counts to detect these complications early.

Melphalan should not be used in patients with known hypersensitivity to melphalan or other nitrogen‑mustard agents, in pregnant or breastfeeding women, and in individuals with severe renal impairment unless dose adjustments are made. Caution is also advised for patients with active uncontrolled infections or significant bone‑marrow failure.